Research Paper Volume 15, Issue 23 pp 13646—13654
Cabozantinib prevents AGEs-induced degradation of type 2 collagen and aggrecan in human chondrocytes
Figure 7. Silencing SOX-9 abolished the effect of Cabozantinib on type II collagen and aggrecan levels in AGEs-treated SW1353 chondrocytes. Cells were transfected with the siRNA targeting SOX-9 (siR-SOX-9), followed by stimulated with 100 μg/ml AGEs in the presence or absence of 20 μM Cabozantinib for 24 h. (A) Successful knockdown of SOX-9. (B) The protein level of type II collagen and Aggrecan was determined by the ELISA assay (n=6, *, ** P<0.05, 0.01 vs. Control group, #, ## P<0.05, 0.01 vs. AGEs group, ※P<0.05 vs. Cabozantinib group).